研究者詳細 - 寺井　崇二

論文 - 寺井　崇二

分割表示 1,167 件中 301 - 320 件目／全件表示 >>

自律神経経路を介した臓器連関と肝疾患

上村顕也, 大脇崇史, 高昌良, 永山逸夫, 名古屋拓郎, 井上良介, 上野将紀, 寺井崇二

日本自律神経学会総会プログラム・抄録集 74回 87 - 87 2021年10月

胆管への浸潤を伴う胆管内乳頭状粘液性腺癌 1症例報告(Intraductal papillary mucinous adenocarcinoma with bile duct invasion: A case report)

水戸將貴, 戸田遼, 木村究, 小島雄一, 小川光平, 木村成宏, 荒生祥尚, 五十嵐聡, 林和直, 土屋淳紀, 寺井崇二, 加藤卓, 味岡洋一, 石川博補, 滝沢一泰, 若井俊文

日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集 69回・91回 53 - 53 2021年10月

原発性胆汁性胆管炎患者の予後を最もよく予想する治療反応性判定Criteriaについて

木村成宏, 高村昌昭, 武田信峻, 荒生祥尚, 高綱将史, 渡邉雄介, 竹内卓, 阿部寛幸, 薛徹, 上村博輝, 坂牧僚, 上村顕也, 土屋淳紀, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増大会 ) A698 - A698 2021年10月

消化器診療におけるサルコペニアの意義 1-kestoseが高齢サルコペニアの腸内細菌と筋肉量に与える影響

冨永顕太郎, 土屋淳紀, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増大会 ) A461 - A461 2021年10月

原発性胆汁性胆管炎患者の予後を最もよく予想する治療反応性判定Criteriaについて

木村成宏, 高村昌昭, 武田信峻, 荒生祥尚, 高綱将史, 渡邉雄介, 竹内卓, 阿部寛幸, 薛徹, 上村博輝, 坂牧僚, 上村顕也, 土屋淳紀, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増大会 ) A698 - A698 2021年10月

有症化した症候性巨大肝嚢胞に対して、ミノサイクリン硬化療法が著効した一例

木南佳也, 小川和也, 石井壮一, 遠藤沙織, 石川夏生, 阿部寛幸, 佐藤裕樹, 坂牧僚, 上村顕也, 寺井崇二

日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集 69回・91回 93 - 93 2021年10月

Interventional EUS超音波内視鏡下瘻孔形成術の現状と問題点(膵) 重症急性膵炎後Walled-off necrosisの自然軽快に関連する因子

五十嵐聡, 林和直, 寺井崇二

日本消化器病学会雑誌 118 ( 臨増大会 ) A550 - A550 2021年10月

大腸がん検診を受診しない理由に関するアンケート調査

水野研一, 川田雄三, 林和直, 寺井崇二, 中島尚

日本消化器病学会雑誌 118 ( 臨増大会 ) A706 - A706 2021年10月

超音波内視鏡システムにおける音速補正モードの膵癌診断における有用性の検討

林和直, 小川光平, 五十嵐聡, 寺井崇二

Gastroenterological Endoscopy 63 ( Suppl.2 ) 2046 - 2046 2021年10月

当院における自己免疫性膵炎およびIgG4関連硬化性胆管炎の内視鏡診断と治療

小川光平, 五十嵐聡, 林和直, 寺井崇二

Gastroenterological Endoscopy 63 ( Suppl.2 ) 2073 - 2073 2021年10月

Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice. 国際誌

Shunsuke Nojiri, Atsunori Tsuchiya, Kazuki Natsui, Suguru Takeuchi, Takayuki Watanabe, Yuichi Kojima, Yusuke Watanabe, Hiroteru Kamimura, Masahiro Ogawa, Satoko Motegi, Takahiro Iwasawa, Takeki Sato, Masaru Kumagai, Yui Ishii, Tomomi Kitayama, Yu-Tung Li, Yuya Ouchi, Takashi Shimbo, Masaaki Takamura, Katsuto Tamai, Shuji Terai

Inflammation and regeneration 41 ( 1 ) 28 - 28 2021年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

The liver has a high regenerative ability and can induce spontaneous regression of fibrosis when early liver damage occurs; however, these abilities are lost when chronic liver damage results in decompensated cirrhosis. Cell therapies, such as mesenchymal stem cell (MSC) and macrophage therapies, have attracted attention as potential strategies for mitigating liver fibrosis. Here, we evaluated the therapeutic effects of HMGB1 peptide synthesized from box A of high mobility group box 1 protein. Liver damage and fibrosis were evaluated using a carbon tetrachloride (CCl4)-induced cirrhosis mouse model. The effects of HMGB1 peptide against immune cells were evaluated by single-cell RNA-seq using liver tissues, and those against monocytes/macrophages were further evaluated by in vitro analyses. Administration of HMGB1 peptide did not elicit a rapid response within 36 h, but attenuated liver damage after 1 week and suppressed fibrosis after 2 weeks. Fibrosis regression developed over time, despite continuous liver damage, suggesting that administration of this peptide could induce fibrolysis. In vitro analyses could not confirm a direct effect of HMGB1 peptide against monocyte/macrophages. However, macrophages were the most affected immune cells in the liver, and the number of scar-associated macrophages (Trem2+Cd9+ cells) with anti-inflammatory markers increased in the liver following HMGB1 treatment, suggesting that indirect effects of monocytes/macrophages were important for therapeutic efficacy. Overall, we established a new concept for cell-free therapy using HMGB1 peptide for cirrhosis through the induction of anti-inflammatory macrophages.

DOI： 10.1186/s41232-021-00177-4

PubMed

researchmap

Transition of clinical and basic studies on liver cirrhosis treatment using cells to seek the best treatment. 国際誌

Shuji Terai, Atsunori Tsuchiya, Yusuke Watanabe, Suguru Takeuchi

Inflammation and regeneration 41 ( 1 ) 27 - 27 2021年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

The liver is a highly regenerative organ; however, its regeneration potential is reduced by chronic inflammation with fibrosis accumulation, leading to cirrhosis. With an aim to tackle liver cirrhosis, a life-threatening disease, trials of autologous bone marrow cell infusion (ABMi) therapy started in 2003. Clinical studies revealed that ABMi attenuated liver fibrosis and improved liver function in some patients; however, this therapy has some limitations such as the need of general anesthesia. Following ABMi therapy, studies have focused on specific cells such as mesenchymal stromal cells (MSCs) from a variety of tissues such as bone marrow, adipose tissue, and umbilical cord tissues. Particularly, studies have focused on gaining mechanistic insights into MSC distribution and effects on immune cells, especially macrophages. Several basic studies have reported the use of MSCs for liver cirrhosis models, while a number of clinical studies have used autologous and allogeneic MSCs; however, there are only a few reports on the obvious substantial effect of MSCs in clinical studies. Since then, studies have analyzed and identified the important signals or components in MSCs that regulate immune cells, such as macrophages, under cirrhotic conditions and have revealed that MSC-derived exosomes are key regulators. Researchers are still seeking the best approach and filling the gap between basic and clinical studies to treat liver cirrhosis. This paper highlights the timeline of basic and clinical studies analyzing ABMi and MSC therapies for cirrhosis and the scope for future studies and therapy.

DOI： 10.1186/s41232-021-00178-3

PubMed

researchmap

Advances in the Treatment of Gastrointestinal Bleeding: Safety and Efficiency of Transnasal Endoscopy. 国際誌

Hiroyuki Abe, Kenya Kamimura, Yoshihisa Arao, Junji Kohisa, Shuji Terai

Medicines (Basel, Switzerland) 8 ( 9 ) 2021年9月

記述言語：英語

Acute upper gastrointestinal bleeding (UGIB) is a common disorder and a gastroenterological emergency. With the development of new techniques and devices, the survivability after gastrointestinal bleeding is improving. However, at the same time, we are facing the difficulty of severely complicated cases with various diseases. For example, while endoscopic examination with a normal diameter endoscope is essential for the diagnosis and treatment of UGIB, there are several cases in which it cannot be used. In these cases, transnasal endoscopy (TNE) may be a viable treatment option. This report reviews current hemostatic devices for endoscopic treatment and the safety and efficiency of using TNE in complicated cases. The latter will be demonstrated in a case report where TNE was employed in a patient with severe esophageal stenosis. This review summarizes the advances made in the devices used and will provide further ideas for the physician in terms of combining these devices and TNE.

DOI： 10.3390/medicines8090053

PubMed

researchmap

【肝疾患エキスパートブック栄養管理に活かすための最新情報】(Part 1)肝硬変肝硬変に対する運動療法について

上村博輝, 寺井崇二, 眞田菜緒, 小師優子

臨床栄養 139 ( 4 ) 445 - 451 2021年9月

【膵癌研究最前線】膵臓選択的ハイドロダイナミック遺伝子導入法

柴田理, 上村顕也, 田中裕登, 小川光平, 阿部寛幸, 五十嵐聡, 横尾健, 寺井崇二

消化器・肝臓内科 10 ( 3 ) 342 - 346 2021年9月

急性肝障害からの回復の予測バイオマーカーとしての血中セロトニン測定の意義

薛徹, 上村顕也, 大脇崇史, 荒生祥尚, 横尾健, 坂牧僚, 上村博輝, 土屋淳紀, 高村昌昭, 寺井崇二

肝臓 62 ( Suppl.2 ) A536 - A536 2021年9月

消化器領域における再生医療の研究と新たな臨床応用肝硬変に対する間葉系幹細胞やそのエクソソームを用いた治療法開発を目指して

土屋淳紀, 高村昌昭, 寺井崇二

肝臓 62 ( Suppl.2 ) A533 - A533 2021年9月

肝硬変の近未来診療肝硬変の線維化改善を目指したHMGB1部分ペプチド療法の基礎検討と医師主導治験への展開

土屋淳紀, 高村昌昭, 寺井崇二

肝臓 62 ( Suppl.2 ) A511 - A511 2021年9月

The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan. 国際誌

Akira Sakamaki, Kenya Kamimura, Takeshi Yokoo, Akihiko Osaki, Seiichi Yoshikawa, Yoshihisa Arao, Toru Setsu, Hiroteru Kamimura, Nobuo Waguri, Manabu Takeuchi, Kazuhiro Funakoshi, Shuji Terai

Medicine 100 ( 32 ) e26902 2021年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

ABSTRACT: Gastrointestinal bleeding, hepatic encephalopathy (HE), and hepatocarcinogenesis are associated with the prognosis of patients with liver cirrhosis (LC). Proton pump inhibitors (PPIs) have been used to prevent bleeding, however the effects of PPIs on overall survival have not yet been elucidated. Therefore, this multicenter retrospective study aimed to assess the effect of PPI on the prognosis and HE occurrence of the patients with liver cirrhosis in Japan.A total of 456 patients diagnosed with LC at the 4 institutes during the study period (2010-2014) were assessed. PPI-treated and non-treated patients were compared using propensity score matching analysis. Primary and secondary endpoints of the study were set as the occurrence of HE and overall survival, respectively.A comparison of all cases showed a significantly poorer hepatic reserve function in the PPI-treated patients. The propensity-score matching analysis was performed and 120 PPI-treated patients were 1:1 matched with non-treated patients. The analysis revealed a higher incidence of HE in the PPI-treated than in the non-treated patients (P = .032; hazard ratio [HR], 2.162; 95% confidence interval [CI], 1.066-4.176), but the prognosis of PPI-treated patients was no worse than that of non-treated patients (P = .676; HR, 1.101; 95% CI, 0.702-1.726).This retrospective study showed that PPI administration for the patients with liver cirrhosis may partly be related to the increased incidence of HE but not worsen the patient prognosis.

DOI： 10.1097/MD.0000000000026902

PubMed

researchmap

A Rare Case of Ulcerative Colitis with Severe Pneumocystis jirovecii Pneumonia and Cytomegalovirus Colitis: A Case Report and Literature Review.

Yusuke Watanabe, Kazunao Hayashi, Shuji Terai

Internal medicine (Tokyo, Japan) 2021年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

Pneumocystis jirovecii pneumonia (PJP) and cytomegalovirus (CMV) colitis are opportunistic infections that occur during immunosuppressive treatments for ulcerative colitis (UC). The prognosis of PJP and CMV colitis is very poor. We herein report a rare case of a 74-year-old UC patient with PJP and CMV colitis that was successfully treated with intensive therapy. PJP progresses rapidly, so the timing and choice of treatment are critical. Furthermore, a literature review of similar cases suggested that prophylactic therapy for opportunistic infections might be important, especially in the elderly. This case will serve as a reference for successful treatment in future cases.

DOI： 10.2169/internalmedicine.7953-21

PubMed

researchmap

　前のページ - 次のページ　

<寺井 崇二>

論文 - 寺井 崇二

<寺井　崇二>

論文 - 寺井　崇二